Details

Autor(en) / Beteiligte

• Leruez‐Ville, M
• Seng, R
• Morand, P
• Boufassa, F
• Boue, F
• Deveau, C
• Rouzioux, C
• Goujard, C
• Seigneurin, JM
• Meyer, L

Titel

Blood Epstein–Barr virus DNA load and risk of progression to AIDS‐related systemic B lymphoma

Ist Teil von

• HIV medicine, 2012-09, Vol.13 (8), p.479-487

Ort / Verlag

England

Erscheinungsjahr

2012

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Background AIDS‐related lymphoma (ARL) remains the main cause of AIDS‐related deaths in the combined antiretroviral therapy (cART) era. Although most ARLs are associated with the Epstein–Barr virus (EBV), whether patients with high EBV burden are more at risk of developing ARL is unknown. This study investigated the relationship between high blood EBV DNA loads and subsequent progression to ARL. Methods We identified 43 cases of ARL diagnosed between 1988 and 2007 within two cohorts (ANRS SEROCO/HEMOCO and PRIMO) and for which stored serum and peripheral blood mononuclear cell (PBMC) samples were available within 3 years before ARL diagnosis. For each case, two controls matched for the cohort and CD4 cell count in the year of ARL diagnosis were selected. EBV DNA was measured in PBMCs and serum samples with a commercial kit. Results High levels of EBV DNA in PBMCs collected a median of 10 months before diagnosis were associated with an increased risk of developing systemic B lymphoma (adjusted odds ratio 2.47; 95% confidence interval 1.15; 5.32 for each 1 log copies/106 PBMC increase in EBV load) but not with primary brain lymphoma. Conclusion In this study, HIV‐infected patients with undetectable EBV DNA in PBMCs did not develop ARL in the following 3 years, while high levels of EBV DNA in PBMCs predicted subsequent progression to systemic B lymphoma. Clinicians should be aware of the increased risk of developing systemic B lymphoma in HIV‐infected patients with a high blood EBV DNA load.